[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577828":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":25,"studyPopulation":18,"armGroups":26,"interventions":40,"overallOfficials":46,"centralContacts":51,"locations":57,"responsibleParty":73,"collaborators":18,"id":75,"slug":18,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":18,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":18,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":18,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Beijing Municipal Administration of Hospitals","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":18},[9],{"measure":10,"description":11,"timeFrame":12},"Sustained response rate and relapse rate by virological and serological indicators","The levels of biochemical, AFP, HBV DNA, HBV RNA, HBsAg, anti-HBs, HBeAg, anti-He, anti-He, HBcrAg and anti-HBc measured the expression of frequency and functional molecules of peripheral blood pDC and Treg cells and the plasma levels of IFN- γ, IP-10, IL-10 and TGF- β","Conduct testing every 3-6 months",[14],{"measure":15,"description":16,"timeFrame":17},"The incidence of hepatitis and liver cancer","The incidence of hepatitis and liver cancer among the enrolled researchers during the research process\n\nThe incidence of hepatitis and liver cancer among the enrolled researchers during the research process\n\nThe incidence of hepatitis and liver cancer among the enrolled researchers during the research process.","36 months",null,{"allocation":20,"interventionModel":21,"interventionModelDescription":18,"primaryPurpose":22,"observationalModel":18,"timePerspective":18,"maskingInfo":23},"RANDOMIZED","PARALLEL","OTHER",{"masking":24,"maskingDescription":18,"whoMasked":18},"NONE","Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. Group A has an anti HBs titer ≥ 100mIU\u002Fml and is followed up every 3-6 months for observation. The anti HBs titers\\\u003C100mIU\u002Fml were randomly divided into two groups: Group B and Group C. Group B did not intervene and was followed up every 3-6 months for observation; In group C, 20 micrograms of recombinant hepatitis B vaccine were injected subcutaneously three times on day 0, January and March. For group C patients, the level of anti HBs was detected at the 4th month after the initial vaccination. For those who could not produce anti HBs (anti HBs\\\u003C10mIU\u002Fml), the recombinant hepatitis B vaccine was subcutaneously injected three times, 20 μ g each time, in 0 day, January and March. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations were conducted every 3-6 months, and blood samples were retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.",[27,31,34],{"label":28,"type":29,"description":30,"interventionNames":18},"Group A:baseline anti-HBs titer≥100 mIU\u002Fml","NO_INTERVENTION","Patients with anti-HBs titer ≥100 mIU\u002Fml at baseline were selected as group A",{"label":32,"type":29,"description":33,"interventionNames":18},"Group B:baseline anti-HBs titer\u003C100 mIU\u002Fml","Patients with anti-HBs titer\\\u003C100 mIU\u002Fml at baseline were randomly divided into group B and group C, and group B did not receive intervention",{"label":35,"type":36,"description":37,"interventionNames":38},"Group C:baseline anti-HBs titer\u003C100 mIU\u002Fml","EXPERIMENTAL","Patients with anti-HBs titer\\\u003C100 mIU\u002Fml at baseline were randomly divided into group B and group C, and group C received hepatitis B vaccine injection.",[39],"Biological: baseline anti-HBs titer",[41],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":18},"BIOLOGICAL","baseline anti-HBs titer","Patients with baseline anti-HBs titer\\\u003C100 mIU\u002Fml were randomly divided into two groups, group B and group C. Group B did not intervene, while group C received hepatitis B vaccine intervention and observed its indicators.",[35],[47],{"name":48,"affiliation":49,"role":50},"Minghui Li","Beijing Ditan Hospital","PRINCIPAL_INVESTIGATOR",[52],{"name":53,"role":54,"phone":55,"phoneExt":18,"email":56},"Lu Zhang","CONTACT","13581975577","zhanglu1218@126.com",[58],{"facility":49,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Beijing","Beijing Municipality","100015","China","CN",{"type":66,"coordinates":67},"Point",[68,69],116.39723,39.9075,{"lat":69,"lon":68},[72],{"name":53,"role":54,"phone":55,"phoneExt":18,"email":56},{"type":50,"investigatorFullName":48,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Head of Department","100577828",false,"NCT06803368","Research on Clinical Recovery and Maintenance Strategies for CHB","Research on Clinical Recovery and Maintenance Strategies for Chronic Hepatitis B","Inclusion Criteria:\n\n* Age between 18 and 65 years old;\n* Gender is not limited;\n* CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B \\[5\\];\n* Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon;\n* Sign a written informed consent form.\n\nExclusion Criteria:\n\n* Merge with other hepatitis virus (HCV, HDV) infections;\n* Autoimmune liver disease;\n* HIV infection;\n* Long term alcohol abuse and\u002For other liver damaging drugs;\n* Mental illness;\n* Evidence of liver tumors (liver cancer or AFP\\>100ng\u002Fml);\n* Decompensated cirrhosis;\n* Individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up.","ALL","18 Years","65 Years",{"count":85,"type":86},285,"ESTIMATED","INTERVENTIONAL",[89],"NA","Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.",[92,93],"Chronic Hepatitis b","Hepatitis B Vaccine","2025-01-26",{"date":96,"type":97},"2025-01-31","ACTUAL",{"date":99,"type":97},"2024-11-01",{"date":101,"type":86},"2027-10-30",{"name":5,"class":6},1]